Last email, I highlighted a recent publication from Ashish Kamat outlining key definitions and endpoints in bladder cancer studies. Just to level set, please check in on the AUA/SUO definitions of NMIBC risk groups. This is critical for understanding which patients should be getting what therapy.

At noon on Thursday, Mark Tyson will present the first results of BOND-003 examining Cretostimogene grenadenorepvec as treatment for patients with high-risk BCG-unresponsive NMIBC. Check out this link to better understand how this trial was designed and which questions it seeks to answer.

As a sneak peak of what we may expect from the phase 3 BOND-003 trial, check out this publication from a few years ago reporting single arm, phase 2 results.

After Dr. Tyson’s presentation, Sandip Patel will present results of the ENVISION trial examining primary chemoablation with UGN-102 for patients with recurrent, low-grade intermediate risk non-muscle invasive bladder cancer. To better understand the context for this presentation, check out this interview with Mark Schoenberg that gives some background on this therapeutic approach and the studies assessing this drug.

This treatment approach has also been assessed in the ATLAS trial which was published in the Journal of Urology over the summer. Check out a summary of the publication here, with links to the full manuscript if you want to digest all the data yourself.